ReviewAdvances in therapy2020

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.

Pietro Lampertico et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.